Elevation Oncology Inc ELEV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Elevation Oncology Gets FDA Fast-Track Designation for EO-3021
-
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
-
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
-
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
Trading Information
- Previous Close Price
- $0.60
- Day Range
- $0.54–0.62
- 52-Week Range
- $0.36–5.83
- Bid/Ask
- $0.56 / $0.58
- Market Cap
- $33.12 Mil
- Volume/Avg
- 2,555 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Comparables
Valuation
|
Metric
|
ELEV
|
ARTV
|
CCCC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.38 | — | 1.55 |
Price/Sales | — | 4.27 | 11.25 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELEV
|
ARTV
|
CCCC
|
|---|---|---|---|
Quick Ratio | 40.12 | 4.43 | 4.89 |
Current Ratio | 41.10 | 4.59 | 5.09 |
Interest Coverage | — | — | −715.67 |
Quick Ratio
ELEV
ARTV
CCCC
Profitability
|
Metric
|
ELEV
|
ARTV
|
CCCC
|
|---|---|---|---|
Return on Assets (Normalized) | −34.92% | −16.21% | −22.53% |
Return on Equity (Normalized) | −52.77% | — | −34.97% |
Return on Invested Capital (Normalized) | −36.70% | — | −30.08% |
Return on Assets
ELEV
ARTV
CCCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Djbtmlmr | Fyj | $530.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fzyhmhcf | Rflyfpj | $121.2 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ndzmggyyq | Fnwfr | $115.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lhfjkhwrb | Vwfhgr | $35.4 Bil | |||
| argenx SE ADR
ARGX
| Hmjndqgk | Cxhyw | $32.8 Bil | |||
| BioNTech SE ADR
BNTX
| Djsvcknl | Tcll | $28.5 Bil | |||
| Moderna Inc
MRNA
| Qztlddm | Lsfp | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Xhhlyzjk | Rbcl | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sblkkyxt | Jyzvtlw | $13.3 Bil | |||
| Incyte Corp
INCY
| Blzmkywpv | Xyxfx | $13.1 Bil |
United States